Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1000 participants
OBSERVATIONAL
2020-08-09
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy
NCT05101629
Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study.
NCT04378023
Construction of a Recurrence Risk Prediction Model for Liver Resection Based on Drug Sensitivity of Patient-derived Hepatocellular Carcinoma Organoid
NCT06699524
Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards
NCT05681949
AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
NCT00427973
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Health-related quality of life in patients with HCC / CCC will be evaluated for up to three years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hepatocellular Carcinoma (HCC)
Patients with Hepatocellular Carcinoma (HCC)
Physician's choice according to patient's needs.
Routine care as per site standard.
Cholangiocarcinoma (CCC)
Patients with Cholangiocarcinoma (CCC)
Physician's choice according to patient's needs.
Routine care as per site standard.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Physician's choice according to patient's needs.
Routine care as per site standard.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 years
* Signed and dated informed consent (IC):
* For participation in the PRO module: Before primary locoregional therapy or start of first systemic treatment
* For no participation in the PRO module: No later than 8 weeks after primary locoregional therapy or start of first systemic treatment
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
iOMEDICO AG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas Berg, Prof.Dr.
Role: STUDY_CHAIR
Leipzig
Peter R. Galle, Prof.Dr.
Role: STUDY_CHAIR
Mainz
Wolf P. Hofmann, Prof.Dr.
Role: STUDY_CHAIR
Berlin
Achim Kautz
Role: STUDY_CHAIR
Köln
Philippe Pereira, Prof.Dr.
Role: STUDY_CHAIR
Heilbronn
Karin Potthoff, Dr.
Role: STUDY_CHAIR
Freiburg im Breisgau
Jan Schröder, PD Dr.
Role: STUDY_CHAIR
Mülheim an der Ruhr
Robert Thimme, Prof.Dr.
Role: STUDY_CHAIR
Freiburg im Breisgau
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Multiple sites all over germany
Multiple Locations, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IOM-100425
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.